Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers-Reference-Cited by-同舟云学术

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers

Published:2019-01-31 Issue:6 Volume:49 Page:723-732
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Keshteli Ammar Hassanzadeh¹,Madsen Karen L.¹,Mandal Rupasri²,Boeckxstaens Guy E.³,Bercik Premysl⁴,De Palma Giada⁴,Reed David E.⁵,Wishart David²⁶,Vanner Stephen⁵,Dieleman Levinus A.¹

Affiliation:

1. Division of Gastroenterology, Department of Medicine; University of Alberta; Edmonton Alberta Canada

2. Department of Biological Sciences; University of Alberta; Edmonton Alberta Canada

3. Department of Gastroenterology; Catholic University of Leuven; Leuven Leuven Belgium

4. Department of Medicine; Farncombe Family Digestive Research Institute, McMaster University; Hamilton Ontario Canada

5. Gastrointestinal Diseases Research Unit; Queen's University; Kingston Ontario Canada

6. Department of Computing Science; University of Alberta; Edmonton Alberta Canada

Funder

Canadian Institutes of Health Research

Alberta Innovates Bio Solutions

Alberta Innovates - Health Solutions

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15141/fullpdf

Reference51 articles.

1. Irritable bowel syndrome: a clinical review;Chey;JAMA,2015

2. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures;Agarwal;Gastroenterol Clin North Am,2011

3. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis;Lovell;Clin Gastroenterol Hepatol,2012

4. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice;Lucak;Therap Adv Gastroenterol,2017

5. Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome;Shankar;Microbiome,2015

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multisample lipidomic profiles of irritable bowel syndrome and irritable bowel syndrome-like symptoms in patients with inflammatory bowel disease: new insight into the recognition of the same symptoms in different diseases;Journal of Gastroenterology;2024-09-10

2. The gut microbiome in disorders of gut–brain interaction;Gut Microbes;2024-07

3. Metabolic biomarkers in irritable bowel syndrome diagnosis;Clinica Chimica Acta;2024-06

4. Urinary metabolome of infants with colic treated with Lactobacillus reuteri DSM 17938: a pilot randomized trial;Minerva Pediatrics;2024-06

5. Identifying Robust Biomarkers for the Diagnosis and Subtype Distinction of Inflammatory Bowel Disease through Comprehensive Serum Metabolomic Profiling;2024-03-25